Wednesday, July 8, 2026

biotech · Genetic Disease · Alport Syndrome · ELOX

Eloxx Pharmaceuticals

Eloxx Pharmaceuticals is a biotech organization headquartered in Watertown, USA. It trades on NYSE under ticker ELOX. Primary therapeutic focus areas include Genetic Disease, Alport Syndrome, Cystic Fibrosis, Genetic Dis

Watertown, USA HQ
2013 Founded
12 Employees
Public company Type
ELOX · NYSE Ticker
Company details
Status
Public
HQ
Watertown, USA
Founded
2013
Employees
12
Programs
7
Drugs
1
Patents
6
Clinical program

ELX-02

Phase 2 · small molecule · Cystic Fibrosis

ELX-02 for Cystic Fibrosis is a Phase 2 program (small_molecule) at Eloxx Pharmaceuticals with 2 ClinicalTrials.gov record(s).

← All Eloxx Pharmaceuticals projects Phase 2 small molecule completed

Internal code EL-004

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Eloxx Pharmaceuticals
Phase
Phase 2
Modality
small_molecule
Indication
Cystic Fibrosis
Status
completed
Trials
2

Clinical trials